Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Geer

Internal Medicine Charleston, SC Medical Doctor

NPI 1497782668 CMS profile 112677

325 Folly Rd Ste 102B, Ste 120, Charleston, SC 29412

Open in the dashboard

General payments

$3,842

237 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Geer of Charleston, SC is reported in the CMS Open Payments database as having received $3,842 across 237 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $46 2
2024 General $14 1
2023 General $92 4
2022 General $1,187 66
2021 General $1,161 72
2020 General $620 41
2019 General $724 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Geer
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Charles Geer were reported at $46. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Charles Geer Internal Medicine median Middle half National median
2019 $724 $159 $48–$570 $163
2020 $620 $119 $33–$402 $114
2021 $1,161 $135 $37–$521 $132
2022 $1,187 $141 $42–$496 $149
2023 $92 $149 $45–$519 $160
2024 $14 $154 $47–$537 $164
2025 $46 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $432 31 payments
  2. AstraZeneca Pharmaceuticals LP $346 23 payments
  3. Lilly USA, LLC $308 19 payments
  4. Amgen Inc. $276 19 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $213 14 payments
  6. AbbVie, Inc. $208 12 payments
  7. GlaxoSmithKline, LLC. $187 10 payments
  8. Novartis Pharmaceuticals Corporation $182 11 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $129 7 payments
  10. Pfizer Inc. $128 8 payments
  11. Other $1,432 83 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,842 237 payments
Products named General payments · program years 2019–2025
  1. Ozempic $382 28 payments
  2. FARXIGA $267 17 payments
  3. RYBELSUS $237 17 payments
  4. TRULICITY $229 14 payments
  5. NURTEC ODT $217 12 payments
  6. JARDIANCE Diabetes $213 14 payments
  7. JARDIANCE Diabetes $210 13 payments
  8. Repatha $196 14 payments
  9. AIMOVIG $172 12 payments
  10. VRAYLAR $169 9 payments
  11. Other $3,061 189 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

237 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record